- Home
- KF vs GLSI Comparison
KF vs GLSI Comparison
Compare KF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KF | GLSI |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.4M | 244.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KF | GLSI |
|---|---|---|
| Price | $67.33 | $15.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 28.1K | ★ 117.3K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.64 | $7.78 |
| 52 Week High | $81.94 | $34.10 |
Technical Indicators
Market Signals| Indicator | KF | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 47.16 |
| Support Level | $66.27 | $14.63 |
| Resistance Level | $67.86 | $29.89 |
| Average True Range (ATR) | 1.91 | 1.49 |
| MACD | 0.47 | -0.08 |
| Stochastic Oscillator | 78.05 | 29.13 |
Price Performance
Historical ComparisonAbout KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, including equity securities, of Korean companies. Its portfolio consists of companies from different sectors such as auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.